PENGEMBANGAN EPITOPHUMAN IMMUNODEFICIENCY VIRUS (HIV-1) DARI ISOLAT INDONESIA MELALUI PENDEKATAN REVERSE VACCINOLOGY

• Main Author: Fauzi, Alidza
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/43017
• Institution: Institut Teknologi Bandung

Human Immunodeficiency Virus (HIV) is a virus that can cause damage to the immune system or AIDS by attacking T helper, macrophages, and dendritic cells. The great variety of HIV causes the necessity of developing vaccines and tests for the prevention and protection of this virus continuously. One method of developing a vaccine or diagnostic kit that can be done is through Reverse Vaccinology (RV) approach. Epitope development method with RV method has been done for several pathogens, but not yet done for the HIV virus, especially the HIV virus that infects patients in Indonesia. Therefore this study tries to develop an HIV epitope as a vaccine candidate or molecular kit using RV. In this research, a case study was carried out which involved extracting HIV-1 sequence data from Indonesian isolates, examining the region of conseved sequences, prediction of vaccine candidate epitopes, and prediction of B cell epitope MHC derivatives. Based on the results of the analysis above, one of the best epitope candidates will be selected to be synthetically made from the German JPT Peptide Technology GmbH. The peptides obtained were then coated on 96 micro plates well, then epitope antigenicity was tested using the Enzyme Linked Immunosorbent Assay (ELISA) method. For control at the coating stage used chicken IgY that has been previously characterized using the SDS-PAGE method and the Bradford method. For positive control of HIV coated epitopes are used from commercial ELISA kits. From the results of studies in silico obtained 5 epitopes that have the desired characteristics. Next the best epitope was chosen, and then the synthetic form was obtained from the German JPT Peptide Technology GmbH. Testing of chicken IgY control and HIV antigen control showed positive results, however, the antigenicity results of selected epitope still showed negative results. Therefore, it can be concluded that in this study epitope candidates have successfully developed HIV in silico. However, testing is still needed to see the antigenicity of the epitope.